{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:42:43Z","timestamp":1779205363719,"version":"3.51.4"},"reference-count":82,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1136\/ijgc-2022-003701","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T06:06:46Z","timestamp":1678946806000},"page":"420-429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Integrating antibody drug conjugates in the management of gynecologic cancers"],"prefix":"10.1016","volume":"33","clinical-trial-number":[{"clinical-trial-number":"nct00849667","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00738699","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01170650","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04697628","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04209855","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04274426","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05041257","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05445778","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04697472","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04907968","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05329545","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04300556","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03748186","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05445778","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03786081","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01170650","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2944-9488","authenticated-orcid":false,"given":"Anca","family":"Chelariu-Raicu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Mahner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen Nadine","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9343-8754","authenticated-orcid":false,"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2022-003701_bb0010","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2022-003701_bb0015","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2022-003701_bb0020","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003701_bb0025","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003701_bb0030","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003701_bb0035","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003701_bb0040","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology\/GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003701_bb0045","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003701_bb0050","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the aurelia open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003701_bb0055","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1200\/JCO.2007.15.1258","article-title":"Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the north-eastern German Society of gynecological oncology ovarian cancer Study Group","volume":"26","author":"Sehouli","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003701_bb0060","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003701_bb0065","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003701_bb0070","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2022-003701_bb0075","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003701_bb0080","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003701_bb0085","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich\u2019s magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1136\/ijgc-2022-003701_bb0090","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/anie.201307628","article-title":"Antibody-Drug conjugates: an emerging concept in cancer therapy","volume":"53","author":"Chari","year":"2014","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1136\/ijgc-2022-003701_bb0095","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003701_bb0100","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003701_bb0105","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003701_bb0110","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ygyno.2013.03.002","article-title":"Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer","volume":"129","author":"Armstrong","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003701_bb0115","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1200\/JCO.2015.63.2596","article-title":"A randomized, double-blind, placebo-controlled, phase III study to assess efficacy and safety of Weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse","volume":"34","author":"Vergote","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003701_bb0120","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ygyno.2015.01.010","article-title":"A randomized double-blind phase III trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD\/doxil\u00ae\/caelyx\u00ae) in combination versus PLD in participants with platinum-resistant ovarian cancer (PROCEED)","volume":"137","author":"Oza","year":"2015","journal-title":"Gynecologic Oncology"},{"key":"10.1136\/ijgc-2022-003701_bb0125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10555-014-9539-8","article-title":"Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications","volume":"34","author":"Vergote","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"10.1136\/ijgc-2022-003701_bb0130","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of forward I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1136\/ijgc-2022-003701_bb0135","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.5512","article-title":"Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FR\u03b1) expression: characterization of antitumor activity in the SORAYA study","volume":"40","author":"Matulonis","year":"2022","journal-title":"JCO"},{"key":"10.1136\/ijgc-2022-003701_bb0140","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ygyno.2007.11.020","article-title":"Folate receptor alpha as a tumor target in epithelial ovarian cancer","volume":"108","author":"Kalli","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003701_bb0145","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/277665a0","article-title":"Promotion of microtubule assembly in vitro by taxol","volume":"277","author":"Schiff","year":"1979","journal-title":"Nature"},{"key":"10.1136\/ijgc-2022-003701_bb0150","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1136\/ijgc-2022-003701_bb0155","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nrc2803","article-title":"Microtubules and resistance to tubulin-binding agents","volume":"10","author":"Kavallaris","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1136\/ijgc-2022-003701_bb0160","article-title":"Tubulin inhibitor-based antibody-drug conjugates for cancer therapy","volume":"22","author":"Chen","year":"2017","journal-title":"Molecules"},{"key":"10.1136\/ijgc-2022-003701_bb0165","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2022-003701_bb0170","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2022-003701_bb0175","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","article-title":"Safety and dose modification for patients receiving niraparib","volume":"29","author":"Berek","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-003701_bb0180","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1021\/acs.bioconjchem.7b00062","article-title":"Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates","volume":"28","author":"Sun","year":"2017","journal-title":"Bioconjug Chem"},{"key":"10.1136\/ijgc-2022-003701_bb0185","author":"FDA","year":"2021","journal-title":"FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer"},{"key":"10.1136\/ijgc-2022-003701_bb0190","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovatv 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-003701_bb0195","author":"FDA","year":"2022","journal-title":"FDA grants priority review to mirvetuximab soravtansine for FR\u03b1-high, platinum-resistant ovarian cancer"},{"issue":"15_suppl","key":"10.1136\/ijgc-2022-003701_bb0200","volume":"34","author":"O\u2019Malley","year":"2016","journal-title":"JCO"},{"key":"10.1136\/ijgc-2022-003701_bb0205","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/GCO.0000000000000432","article-title":"The target invites a foe: antibody-drug conjugates in gynecologic oncology","volume":"30","author":"Campos","year":"2018","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1136\/ijgc-2022-003701_bb0210","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ygyno.2019.03.245","article-title":"Antibody-drug conjugates in gynecologic malignancies","volume":"153","author":"Lee","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003701_bb0215","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1158\/1078-0432.CCR-18-3965","article-title":"Phase Ia study of anti-napi2b antibody-drug conjugate lifastuzumab vedotin DNIB0600A in patients with non-small cell lung cancer and platinum-resistant ovarian cancer","volume":"26","author":"Gerber","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2022-003701_bb0220","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ygyno.2020.05.039","article-title":"Phase 1B study of anti-napi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer","volume":"158","author":"Moore","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003701_bb0225","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1158\/1535-7163.MCT-20-0166","article-title":"Dolaflexin: a novel antibody-drug conjugate platform featuring high drug loading and a controlled bystander effect","volume":"20","author":"Yurkovetskiy","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1136\/ijgc-2022-003701_bb0230","article-title":"Updated results from the phase 1 expansion study of upifitamab rilsodotin (upri; xmt-1536), a napi2b-directed dolaflexin antibody drug conjugate (ADC) in ovarian cancer (076)","volume":"166","author":"Richardson","year":"2022","journal-title":"Gynecologic Oncology"},{"key":"10.1136\/ijgc-2022-003701_bb0235","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10549-014-3144-y","article-title":"Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies","volume":"148","author":"Twelves","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/ijgc-2022-003701_bb0240","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1158\/1078-0432.CCR-10-0700","article-title":"Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study","volume":"16","author":"Konner","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2022-003701_bb0245","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1158\/1078-0432.CCR-20-4740","article-title":"First-In-Human phase 1 study of morab-202, an antibody-drug conjugate comprising farletuzumab linked to eribulin mesylate, in patients with folate receptor-\u03b1-positive advanced solid tumors","volume":"27","author":"Shimizu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2022-003701_bb0250","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.19.02085","article-title":"First-In-Human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors","volume":"38","author":"Hassan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1136\/ijgc-2022-003701_bb0255","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.5514","article-title":"A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial # 10150","volume":"40","author":"Lheureux","year":"2022","journal-title":"JCO"},{"issue":"15_suppl","key":"10.1136\/ijgc-2022-003701_bb0260","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.5550","article-title":"Phase 1 dose-escalation study of STRO-002, an antifolate receptor alpha (FR\u03b1) antibody drug conjugate (ADC), in patients with advanced, progressive platinum-resistant\/refractory epithelial ovarian cancer (EOC)","volume":"39","author":"Naumann","year":"2021","journal-title":"JCO"},{"key":"10.1136\/ijgc-2022-003701_bb0265","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Invest New Drugs"},{"key":"10.1136\/ijgc-2022-003701_bb0270","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1002\/cncr.30736","article-title":"Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor \u03b1-targeting antibody-drug conjugate, in patients with solid tumors","volume":"123","author":"Moore","year":"2017","journal-title":"Cancer"},{"issue":"16_suppl","key":"10.1136\/ijgc-2022-003701_bb0275","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.5574","article-title":"Integrated safety summary of single-agent mirvetuximab soravtansine in patients with folate receptor \u03b1 (FR\u03b1) -positive recurrent ovarian cancer: phase 1 and 3 clinical trials","volume":"40","author":"Moore","year":"2022","journal-title":"JCO"},{"key":"10.1136\/ijgc-2022-003701_bb0280","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ygyno.2022.02.010","article-title":"Mitigation and management strategies for ocular events associated with tisotumab vedotin","volume":"165","author":"Kim","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003701_bb0285","doi-asserted-by":"crossref","first-page":"102376","DOI":"10.1016\/j.ctrv.2022.102376","article-title":"Emergence of ocular toxicities associated with novel anticancer therapeutics: what the oncologist needs to know","volume":"105","author":"Ali","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1136\/ijgc-2022-003701_bb0290","author":"FDA","year":"2021","journal-title":"Highlights of prescribing information"},{"key":"10.1136\/ijgc-2022-003701_bb0295","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/(SICI)1097-0142(19961001)78:7<1359::AID-CNCR1>3.0.CO;2-G","article-title":"Ocular toxicity and cancer chemotherapy. A review","volume":"78","author":"al-Tweigeri","year":"1996","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2022-003701_bb0300","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/annonc\/mdy023","article-title":"Anti-napi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study","volume":"29","author":"Banerjee","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-003701_bb0305","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2013.03.024","article-title":"Folate receptor alpha (fra) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy","volume":"130","author":"Despierre","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003701_bb0310","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/PAI.0000000000000476","article-title":"Folate receptor alpha expression in platinum resistant\/refractory ovarian carcinomas and primary endocervical adenocarcinomas","volume":"26","author":"Rubinsak","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1136\/ijgc-2022-003701_bb0315","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003701_bb0320","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/PGP.0b013e3182774562","article-title":"Expression of folate receptor-\u03b1 (fra) in gynecologic malignancies and its relationship to the tumor type","volume":"32","author":"O\u2019Shannessy","year":"2013","journal-title":"Int J Gynecol Pathol"},{"key":"10.1136\/ijgc-2022-003701_bb0325","first-page":"775","article-title":"Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix","volume":"8","author":"Wu","year":"1999","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1136\/ijgc-2022-003701_bb0330","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.bbrc.2017.08.015","article-title":"Folate receptor alpha is associated with cervical carcinogenesis and regulates cervical cancer cells growth by activating ERK1\/2\/c-fos\/c-jun","volume":"491","author":"Liu","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1136\/ijgc-2022-003701_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191972","article-title":"The prognostic value of HER2 in ovarian cancer: a meta-analysis of observational studies","volume":"13","author":"Luo","year":"2018","journal-title":"PLoS One"},{"key":"10.1136\/ijgc-2022-003701_bb0340","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1634\/theoncologist.2015-0149","article-title":"The therapeutic challenge of targeting HER2 in endometrial cancer","volume":"20","author":"Diver","year":"2015","journal-title":"Oncologist"},{"key":"10.1136\/ijgc-2022-003701_bb0345","doi-asserted-by":"crossref","first-page":"36219","DOI":"10.18632\/oncotarget.5283","article-title":"Her2 as a novel therapeutic target for cervical cancer","volume":"6","author":"Oh","year":"2015","journal-title":"Oncotarget"},{"key":"10.1136\/ijgc-2022-003701_bb0350","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ygyno.2006.09.028","article-title":"Ca125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. from the Danish \u201c malova \u201d ovarian cancer study","volume":"104","author":"H\u00f8gdall","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003701_bb0355","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1136\/ijgc-2022-003701_bb0360","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/ijgc-00009577-200207000-00007","article-title":"Tissue and serum CA125 expression in endometrial cancer","volume":"12","author":"Ginath","year":"2002","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2022-003701_bb0365","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1447-0756.2010.01221.x","article-title":"Expression of mucin antigens (MUC1 and MUC16) as a prognostic factor for mucinous adenocarcinoma of the uterine cervix","volume":"36","author":"Togami","year":"2010","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1136\/ijgc-2022-003701_bb0370","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0046-8177(03)00177-1","article-title":"Large-Scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas","volume":"34","author":"Frierson","year":"2003","journal-title":"Hum Pathol"},{"key":"10.1136\/ijgc-2022-003701_bb0375","first-page":"63","article-title":"Mesothelin gene expression and promoter methylation\/hypomethylation in gynecological tumors","volume":"31","author":"Obulhasim","year":"2010","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1136\/ijgc-2022-003701_bb0380","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00404-018-4933-z","article-title":"Mesothelin as a target for cervical cancer therapy","volume":"299","author":"J\u00f6hrens","year":"2019","journal-title":"Arch Gynecol Obstet"},{"key":"10.1136\/ijgc-2022-003701_bb0385","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.ejca.2009.12.019","article-title":"Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients","volume":"46","author":"Bignotti","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2022-003701_bb0390","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1002\/cncr.25891","article-title":"Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (TROP-2) and are highly sensitive to immunotherapy with hrs7, a humanized anti-TROP-2 monoclonal antibody","volume":"117","author":"Varughese","year":"2011","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2022-003701_bb0395","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ajog.2011.06.093","article-title":"Cervical carcinomas overexpress human trophoblast cell-surface marker (TROP-2) and are highly sensitive to immunotherapy with hrs7, a humanized monoclonal anti-TROP-2 antibody","volume":"205","author":"Varughese","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1136\/ijgc-2022-003701_bb0400","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3289-2","article-title":"Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, napi2b","volume":"17","author":"Levan","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1136\/ijgc-2022-003701_bb0405","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/sj.bjc.6605760","article-title":"HI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma","volume":"103","author":"Cocco","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2022-003701_bb0410","first-page":"4075","article-title":"Expression of tissue factor in human cervical carcinoma tissue","volume":"16","author":"Zhao","year":"2018","journal-title":"Exp Ther Med"},{"key":"10.1136\/ijgc-2022-003701_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/S0090-8258(22)01432-9","article-title":"Clinical significance of cadherin-6 expression in primary and recurrent epithelial ovarian cancer and its association with outcomes: a potential therapeutic target for epithelial ovarian cancer (206)","volume":"166","author":"Shintani","year":"2022","journal-title":"Gynecologic Oncology"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24009472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24009472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2022-003701","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:28:18Z","timestamp":1753234098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24009472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1048891X24009472"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2022-003701","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating antibody drug conjugates in the management of gynecologic cancers","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2022-003701","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}